

## WilmerHale Advises Millennium Pharmaceuticals in \$8.8 Billion Acquisition by Takeda

2008-04-10

A team of WilmerHale lawyers advised Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) in connection with its proposed \$8.8 billion acquisition by Takeda Pharmaceutical Company Limited (TSE: 4502) through a cash tender offer. The deal is the largest overseas acquisition by a Japanese drug manufacturer.

Serving as Millennium's M&A counsel in the transaction are WilmerHale lawyers [David Redlick](#), [Hal Leibowitz](#), [Jeffrey Hermanson](#), [Brian Johnson](#), [Emily Babalas](#), [Jason Kropp](#) and [Sonia Bednarowski](#). The M&A team is assisted by antitrust partners [William Kolasky](#) and [Sven Voekler](#), and tax partners [William Schmidt](#) and [Robert Burke](#).

WilmerHale has served as primary outside counsel to Millennium since the early 1990s. Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts that markets VELCADE, a novel cancer product, and has oncology and inflammation product candidates in various stages of development.

Click [here](#) for Millennium Pharmaceutical's complete press release.